Brief: Heartbeam Says Received NSE Letter From FDA For 12-Lead ECG Synthesis Software - SEC Filing
21/11/2025 16:44
Nov 21 (Reuters) - Heartbeam Inc BEAT.O: HEARTBEAM INC - RECEIVES NSE LETTER FROM FDA FOR 12-LEAD ECG SYNTHESIS SOFTWARE - SEC FILING HEARTBEAM INC - EVALUATING LAUNCH OF FDA-CLEARED 3D ECG SYSTEM - SEC FILING HEARTBEAM INC - TO WORK WITH FDA TO RESOLVE NSE ISSUE - SEC FILING Source text: [ID:n0001213900-25-113353] Further company coverage: BEAT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance